Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in ...

A flag flies above the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. Lilly, a pharmaceutical company, employs more than 12.000 people in Indianapolis and ...

Eli Lilly has another promising drug in its portfolio with Foundayo. Its growth rate has been more than 40% in recent ...

By Siddhi Mahatole April 20 (Reuters) - U.S. drugmaker Eli Lilly will buy privately held biotech firm Kelonia Therapeutics ...

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of ...

Eli Lilly has agreed to acquire Kelonia Therapeutics for up to $7 billion, in a deal that would bolster the buyer’s oncology ...

Eli Lilly has agreed to buy privately held cancer biotech Kelonia Therapeutics for up to $7 billion in cash in a deal that bolsters the drugmaker's genetic-medicine capabilities. Eli Lilly on Monday ...

The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.

The deal expands Lilly's in vivo CAR-T cancer therapy pipeline, anchored by a multiple myeloma drug that showed early ...

CNBC's Angelica Peebles reports the latest news on pharmaceuticals.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

B for Kelonia adds a credible in vivo CAR-T platform aimed at multiple myeloma, with a one-time IV delivery and no ...